Angiotech presents positive Adhibit(TM) data at the 19th annual European Congress of Obstetrics and Gynecology
07 April 2006 - 11:30AM
PR Newswire (US)
Surgical adhesion scores were threefold less in patients treated
with Adhibit(TM) VANCOUVER, BC and TORINO, Italy, April 7
/PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today announced positive results
from its Adhibit(TM) Adhesion Prevention Gel Myomectomy Study. The
final data set was presented today by Dr. Lilo Mettler, the study's
principal investigator, at the 19th Annual European Congress of
Obstetrics and Gynecology in Torino, Italy. About the Study This
randomized, controlled, single-blind, clinical study was designed
to evaluate the safety and efficacy of Adhibit in reducing the
incidence and severity of post-operative adhesions when applied
immediately after the removal of uterine fibroids (myomectomy
surgery). The study was conducted at six investigational sites in
Europe, Canada, and the Netherlands Antilles. The trial randomized
71 patients, with 48 patients receiving the Adhibit treatment and
23 patients receiving no post-operative adhesion treatment (the
Control group). Patients were surgically re-examined eight to ten
weeks post- procedure to determine the incidence and severity of
adhesions. Adhibit was shown to reduce post-operative adhesion
formation as measured by the modified American Fertility Society
(mAFS) score, a scoring system that factors in both the extent and
tenacity of adhesions. Patients in the group that were treated with
Adhibit experienced a statistically significant reduction in their
mAFS score when compared with those in the Control group (0.8 (+/-)
2.0 Adhibit group versus 2.6 (+/-) 2.2 Control group; p(equal
sign)0.010). "Consistent with preliminary results, we're encouraged
and pleased that this data indicates Adhibit is safe and
effective," said Dr. Rui Avelar, Chief Medical Officer for
Angiotech. "Adhibit also proved itself to be easily delivered
through a laparoscope, and has the potential to further advance
minimally-invasive surgery in women." About Adhibit(TM) Adhibit is
a fully-synthetic, sprayable hydrogel that is safely resorbed by
the body over 30 days and is designed to reduce or prevent the
formation of post-operative surgical adhesions. Currently approved
in Europe to prevent or reduce post-surgical adhesion formation in
pediatric patients undergoing cardiac surgery, Adhibit is an
Angiotech product that is sold and marketed by Baxter Healthcare
Corporation worldwide, excluding the U.S. Baxter has an option to
license Adhibit in the U.S.; however, Adhibit is not currently
approved for sale in the U.S. About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical company that discovers and develops innovative
treatment solutions for diseases or complications associated with
medical device implants, surgical interventions and acute injury or
trauma. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," and "will" and words of similar
import, constitute "forward-looking statements" within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. FOR ADDITIONAL INFORMATION:
--------------------------- Analysts and Investors: Janet Craig,
VP, Investor Relations & Corporate Communications Angiotech
Pharmaceuticals Inc. (604) 221-7676 ext 6933 Media: Colleen
Beauregard Waggener Edstrom Bioscience (503) 443-7863, Email:
DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Analysts and
Investors: Janet Craig, VP, Investor Relations & Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext
6933; Media: Colleen Beauregard, Waggener Edstrom Bioscience, (503)
443-7863, Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024